Tarsus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Revenue	182.95	17.45	25.82	57.03	-	Upgrade
Revenue Growth (YoY)	948.62%	-32.42%	-54.73%	-	-	Upgrade
Cost of Revenue	66.21	51.91	43.58	43.79	18.83	Upgrade
Gross Profit	116.74	-34.46	-17.76	13.24	-18.83	Upgrade
Selling, General & Admin	237.31	108.7	44.95	25.4	8.17	Upgrade
Operating Expenses	237.31	108.7	44.95	25.4	8.17	Upgrade
Operating Income	-120.57	-143.16	-62.71	-12.16	-27	Upgrade
Interest Expense	-7.85	-3.35	-2.2	-	-	Upgrade
Interest & Investment Income	15.01	10.34	3.5	0.04	0.19	Upgrade
Other Non Operating Income (Expenses)	0.59	-0.1	0.09	-0	-	Upgrade
EBT Excluding Unusual Items	-112.82	-136.27	-61.33	-12.12	-26.81	Upgrade
Gain (Loss) on Sale of Investments	-0.79	0.38	-0.77	-1.58	-	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	-0.07	-	Upgrade
Other Unusual Items	-1.94	-	-	-	-	Upgrade
Pretax Income	-115.55	-135.89	-62.1	-13.77	-26.81	Upgrade
Income Tax Expense	-	-	-0	0.06	0	Upgrade
Net Income	-115.55	-135.89	-62.09	-13.83	-26.81	Upgrade
Net Income to Common	-115.55	-135.89	-62.09	-13.83	-26.81	Upgrade
Shares Outstanding (Basic)	38	29	25	21	6	Upgrade
Shares Outstanding (Diluted)	38	29	25	21	6	Upgrade
Shares Change (YoY)	27.98%	19.35%	19.78%	231.12%	162.72%	Upgrade
EPS (Basic)	-3.07	-4.62	-2.52	-0.67	-4.32	Upgrade
EPS (Diluted)	-3.07	-4.62	-2.52	-0.67	-4.32	Upgrade
Free Cash Flow	-84.59	-119	-49.54	3.16	-21.59	Upgrade
Free Cash Flow Per Share	-2.25	-4.05	-2.01	0.15	-3.48	Upgrade
Gross Margin	63.81%	-197.50%	-68.81%	23.22%	-	Upgrade
Operating Margin	-65.90%	-820.53%	-242.92%	-21.32%	-	Upgrade
Profit Margin	-63.16%	-778.89%	-240.51%	-24.25%	-	Upgrade
Free Cash Flow Margin	-46.24%	-682.04%	-191.88%	5.54%	-	Upgrade
EBITDA	-119.34	-142.28	-62.39	-11.85	-26.9	Upgrade
EBITDA Margin	-65.23%	-	-241.66%	-20.77%	-	Upgrade
D&A For EBITDA	1.23	0.88	0.33	0.31	0.1	Upgrade
EBIT	-120.57	-143.16	-62.71	-12.16	-27	Upgrade
EBIT Margin	-65.90%	-	-242.92%	-21.32%	-	Upgrade
Revenue as Reported	182.95	17.45	25.82	57.03	-	Upgrade

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q